Frontiers in aging最新文献_第8页

Editorial: Aging, personal autonomy and independence. 社论:老龄化、个人自主和独立。

Frontiers in aging Pub Date : 2023-11-07 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1326657

Alan Bruno Silva Vasconcelos, Pablo Jorge Marcos-Pardo, Marzo E Da Silva-Grigoletto

引用次数: 0

Components of navigation ability and their predictors in a community-dwelling sample of older adults. 社区老年人样本中导航能力的组成部分及其预测因素。

Frontiers in aging Pub Date : 2023-10-19 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1239094

Michael J Prevratil, Dorota Kossowska-Kuhn, Nicholas Gray, Neil Charness

{"title":"Components of navigation ability and their predictors in a community-dwelling sample of older adults.","authors":"Michael J Prevratil, Dorota Kossowska-Kuhn, Nicholas Gray, Neil Charness","doi":"10.3389/fragi.2023.1239094","DOIUrl":"https://doi.org/10.3389/fragi.2023.1239094","url":null,"abstract":"Introduction: Navigation, as a complex skill important for independent living, requires a variety of cognitive processes. Current scales tapping components are lengthy and can be burdensome for older adults. Methods: Community-dwelling older adults (n = 380, age 60-90 years) completed an online survey tapping wayfinding, being lost navigating, and needing help navigating. Participants then completed objective measures of navigation ability and self-reported memory ability. Cronbach's α was calculated for navigation subscales consisting of subsets of the Wayfinding Questionnaire and Santa Barbara Sense of Direction Questionnaire, and an exploratory factor analysis (EFA) was conducted. Regression analyses were used to test whether objective navigation, memory, and demographic information navigation predicted navigation subscale performance. Results: Each of the individual subscales demonstrated high reliability. EFA generated five unique factors: routing, mental mapping, navigation in near vicinities, feeling lost in far vicinities, and needing help in far vicinities. Across regression analyses, memory, gender, and performance on the Spatial Orientation Test were significant predictors. Discussion: Navigation is a multi-faceted construct that can be reliably measured using concise surveys. Further research is necessary to understand the intricacies of aging and navigation.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. 免疫衰老和多发性硬化症：炎症对预后和治疗的影响。

Frontiers in aging Pub Date : 2023-10-13 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1234572

Smathorn Thakolwiboon, Elizabeth A Mills, Jennifer Yang, Jonathan Doty, Martin I Belkin, Thomas Cho, Charles Schultz, Yang Mao-Draayer

{"title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration.","authors":"Smathorn Thakolwiboon, Elizabeth A Mills, Jennifer Yang, Jonathan Doty, Martin I Belkin, Thomas Cho, Charles Schultz, Yang Mao-Draayer","doi":"10.3389/fragi.2023.1234572","DOIUrl":"10.3389/fragi.2023.1234572","url":null,"abstract":"Aging is associated with a progressive decline of innate and adaptive immune responses, called immunosenescence. This phenomenon links to different multiple sclerosis (MS) disease courses among different age groups. While clinical relapse and active demyelination are mainly related to the altered adaptive immunity, including invasion of T- and B-lymphocytes, impairment of innate immune cell (e.g., microglia, astrocyte) function is the main contributor to disability progression and neurodegeneration. Most patients with MS manifest the relapsing-remitting phenotype at a younger age, while progressive phenotypes are mainly seen in older patients. Current disease-modifying therapies (DMTs) primarily targeting adaptive immunity are less efficacious in older patients, suggesting that immunosenescence plays a role in treatment response. This review summarizes the recent immune mechanistic studies regarding immunosenescence in patients with MS and discusses the clinical implications of these findings.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults. 老药新招：二甲双胍在老年人流感和严重急性呼吸系统综合征冠状病毒2型感染和疫苗接种反应中的作用。

Frontiers in aging Pub Date : 2023-10-11 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1272336

Dominique E Martin, Andreia N Cadar, Jenna M Bartley

{"title":"Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.","authors":"Dominique E Martin, Andreia N Cadar, Jenna M Bartley","doi":"10.3389/fragi.2023.1272336","DOIUrl":"10.3389/fragi.2023.1272336","url":null,"abstract":"In the face of global pathogens such as influenza (flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), strategies beyond standard vaccines and virus-specific treatments are critically needed for older populations who are more susceptible to severe disease and death from these infections due to age-related immune dysregulation. Thus, complimentary therapeutics are needed to address the increased risk of complications and death in older adults. Metformin, an FDA approved diabetes drug, is an attractive therapeutic candidate to improve immune defenses and resilience in older adults facing viral challenge. Metformin is already a candidate anti-aging drug, but its benefits have potential to span beyond this and improve specific immune responses. Metformin can target multiple aging hallmarks as well as directly impact innate and adaptive immune cell subsets. Both retrospective and prospective studies have demonstrated metformin's efficacy in improving outcomes after SARS-CoV-2 or flu infections. Moreover, evidence from clinical trials has also suggested that metformin treatment can improve vaccination responses. In totality, these findings suggest that metformin can improve age-related declines in immunological resilience. Strategies to improve outcomes after infection or improve vaccine-induced protection are invaluable for older adults. Moreover, the ability to repurpose an already FDA approved drug has significant advantages in terms of necessary time and resources. Thus, metformin has great potential as a therapeutic to improve age-related immune dysregulation during flu and SARS-CoV-2 infections and should be further explored to confirm its ability to improve overall immunological resilience in older adults.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54232716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A cluster of X-linked miRNAs are de-repressed with age in mouse liver and target growth hormone signaling. 在小鼠肝脏和靶向生长激素信号传导中，一簇X连接的miRNA随着年龄的增长而被抑制。

Frontiers in aging Pub Date : 2023-10-10 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1261121

Anna P Petrashen, Yufei Lin, Bianca Kun, Jill A Kreiling

引用次数: 0

Impact of senolytic treatment on immunity, aging, and disease. senolytic治疗对免疫力、衰老和疾病的影响。

Frontiers in aging Pub Date : 2023-10-10 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1161799

Erica C Lorenzo, Blake L Torrance, Laura Haynes

{"title":"Impact of senolytic treatment on immunity, aging, and disease.","authors":"Erica C Lorenzo, Blake L Torrance, Laura Haynes","doi":"10.3389/fragi.2023.1161799","DOIUrl":"10.3389/fragi.2023.1161799","url":null,"abstract":"Cellular senescence has been implicated in the pathophysiology of many age-related diseases. However, it also plays an important protective role in the context of tumor suppression and wound healing. Reducing senescence burden through treatment with senolytic drugs or the use of genetically targeted models of senescent cell elimination in animals has shown positive results in the context of mitigating disease and age-associated inflammation. Despite positive, albeit heterogenous, outcomes in clinical trials, very little is known about the short-term and long-term immunological consequences of using senolytics as a treatment for age-related conditions. Further, many studies examining cellular senescence and senolytic treatment have been demonstrated in non-infectious disease models. Several recent reports suggest that senescent cell elimination may have benefits in COVID-19 and influenza resolution and disease prognosis. In this review, we discuss the current clinical trials and pre-clinical studies that are exploring the impact of senolytics on cellular immunity. We propose that while eliminating senescent cells may have an acute beneficial impact on primary immune responses, immunological memory may be negatively impacted. Closer investigation of senolytics on immune function and memory generation would provide insight as to whether senolytics could be used to enhance the aging immune system and have potential to be used as therapeutics or prophylactics in populations that are severely and disproportionately affected by infections such as the elderly and immunocompromised.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54232715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The untapped potential of targeting NRF2 in neurodegenerative disease. 在神经退行性疾病中靶向NRF2的未开发潜力。

Frontiers in aging Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1270838

Wei-Tai Chen, Matthew Dodson

{"title":"The untapped potential of targeting NRF2 in neurodegenerative disease.","authors":"Wei-Tai Chen, Matthew Dodson","doi":"10.3389/fragi.2023.1270838","DOIUrl":"10.3389/fragi.2023.1270838","url":null,"abstract":"Since its initial discovery almost three decades ago, the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) has been shown to regulate a host of downstream transcriptional responses and play a critical role in preventing or promoting disease progression depending on the context. Critically, while the importance of proper nuclear factor erythroid 2-related factor 2 function has been demonstrated across a variety of pathological settings, the ability to progress NRF2-targeted therapeutics to clinic has remained frustratingly elusive. This is particularly true in the case of age-related pathologies, where nuclear factor erythroid 2-related factor 2 is a well-established mitigator of many of the observed pathogenic effects, yet options to target this pathway remain limited. Along these lines, loss of nuclear factor erythroid 2-related factor 2 function has clearly been shown to enhance neuropathological outcomes, with enhancing nuclear factor erythroid 2-related factor 2 pathway activation to prevent neurodegenerative/neurological disease progression continuing to be an active area of interest. One critical obstacle in generating successful therapeutics for brain-related pathologies is the ability of the compound to cross the blood brain barrier (BBB), which has also hampered the implementation of several promising nuclear factor erythroid 2-related factor 2 inducers. Another limitation is that many nuclear factor erythroid 2-related factor 2 activators have undesirable off-target effects due to their electrophilic nature. Despite these constraints, the field has continued to evolve, and several viable means of targeting nuclear factor erythroid 2-related factor 2 in a neuropathological context have emerged. In this perspective, we will briefly discuss the key findings and promising therapeutic options that have been discovered to date, as well as highlight emerging areas of NRF2-neurodegeneration research that provide hope for successfully targeting this pathway in the future.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loop diuretics association with Alzheimer's disease risk. 环状利尿剂与阿尔茨海默病风险的关系。

IF 3.3

Frontiers in aging Pub Date : 2023-09-25 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1211571

Anna Graber-Naidich, Justin Lee, Kyan Younes, Michael D Greicius, Yann Le Guen, Zihuai He

{"title":"Loop diuretics association with Alzheimer's disease risk.","authors":"Anna Graber-Naidich, Justin Lee, Kyan Younes, Michael D Greicius, Yann Le Guen, Zihuai He","doi":"10.3389/fragi.2023.1211571","DOIUrl":"10.3389/fragi.2023.1211571","url":null,"abstract":"Objectives: To investigate whether exposure history to two common loop diuretics, bumetanide and furosemide, affects the risk of developing Alzheimer's disease (AD) after accounting for socioeconomic status and congestive heart failure. Methods: Individuals exposed to bumetanide or furosemide were identified in the Stanford University electronic health record using the de-identified Observational Medical Outcomes Partnership platform. We matched the AD case cohort to a control cohort (1:20 case:control) on gender, race, ethnicity, and hypertension, and controlled for variables that could potentially be collinear with bumetanide exposure and/or AD diagnosis. Among individuals older than 65 years, 5,839 AD cases and 116,103 matched controls were included. A total of 1,759 patients (54 cases and 1,705 controls) were exposed to bumetanide. Results: After adjusting for socioeconomic status and other confounders, the exposure of bumetanide and furosemide was significantly associated with reduced AD risk (respectively, bumetanide odds ratio [OR] = 0.23; 95% confidence interval [CI], 0.15-0.36; p = 4.0 × 10-11; furosemide OR = 0.42; 95% CI, 0.38-0.47; p < 2.0 × 10-16). Discussion: Our study replicates in an independent sample that a history of bumetanide exposure is associated with reduced AD risk while also highlighting an association of the most common loop diuretic (furosemide) with reduced AD risk. These associations need to be additionally replicated, and the mechanism of action remains to be investigated.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41222098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of quantitative biomarkers of aging in human PBMCs. 人类PBMC衰老定量生物标志物的评估。

Frontiers in aging Pub Date : 2023-09-15 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1260502

Brady M Owen, James Phie, Jennifer Huynh, Scott Needham, Cameron Fraser

{"title":"Evaluation of quantitative biomarkers of aging in human PBMCs.","authors":"Brady M Owen, James Phie, Jennifer Huynh, Scott Needham, Cameron Fraser","doi":"10.3389/fragi.2023.1260502","DOIUrl":"https://doi.org/10.3389/fragi.2023.1260502","url":null,"abstract":"Functional decline with age contributes significantly to the burden of disease in developed countries. There is growing interest in the development of therapeutic interventions which slow or even reverse aging. Time and cost constraints prohibit the testing of a large number of interventions for health and lifespan extension in model organisms. Cell-based models of aging could enable high throughput testing of potential interventions. Despite extensive reports in the literature of cell properties that correlate with donor age, few are robustly observed across different laboratories. This casts doubt on the extent that aging signatures are captured in cultured cells. We tested molecular changes previously reported to correlate with donor age in peripheral blood mononuclear cells (PBMCs) and evaluated their suitability for inclusion in a panel of functional aging measures. The tested measures spanned several pathways implicated in aging including epigenetic changes, apoptosis, proteostasis, and intracellular communication. Surprisingly, only two markers correlated with donor age. DNA methylation age accurately predicted donor age confirming this is a robust aging biomarker. Additionally, the apoptotic marker CD95 correlated with donor age but only within subsets of PBMCs. To demonstrate cellular rejuvenation in response to a treatment will require integration of multiple read-outs of cell function. However, building a panel of measures to detect aging in cells is challenging and further research is needed to identify robust predictors of age in humans.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two vicious circles associated with the aging of the immune system in the development of severe forms of COVID-19. 在严重形式的新冠肺炎发展过程中，与免疫系统衰老相关的两个恶性循环。

Frontiers in aging Pub Date : 2023-09-14 eCollection Date: 2023-01-01 DOI: 10.3389/fragi.2023.1260053

Miodrag Vrbic, Ana Milinkovic

{"title":"Two vicious circles associated with the aging of the immune system in the development of severe forms of COVID-19.","authors":"Miodrag Vrbic, Ana Milinkovic","doi":"10.3389/fragi.2023.1260053","DOIUrl":"https://doi.org/10.3389/fragi.2023.1260053","url":null,"abstract":"Background: The immune-inflammatory response is the basis of the pathophysiology of SARS-Cov-2 infection. In severe cases of COVID-19 uncontrolled systemic inflammatory response causes multiorgan dysfunction (MODS), as the most common immediate cause of death. Unfavorable outcome of the COVID-19 most often occurs in elderly patients. The aim of the study was to establish parameters with prognostic significance in severe cases of COVID-19 according to life years, laboratory markers of sepsis and MODS, as well as the number of peripheral CD4+ and CD8+T lymphocytes in 20 consecutively selected critically ill patients. Results: Eleven subjects were male, 9 female, mean age 73.45 ± 11.59, among which the oldest patient was 94 and the youngest 43 years. All the patients met the sepsis and MODS criteria. Increased age and low CD4+ and CD8+T cell counts were identified as independent predictors of death. Only the two youngest patients (43 and 50 years old) survived 28 days, and they are the only ones with a CD4 lymphocyte count above 500 cells/mm3. Conclusion: Senescence of the immune system is mostly characterized by reduced regenerative capacity of adaptive immunity with diminished ability to respond to new antigens and a manifested proinflammatory phenotype. Additional reduction of protective capacity by further deterioration of T cell quantity and quality due to sepsis itself and mutual interaction of senescent T cells and vascular endothelial cells in the induction of cytokine storm represent two complementary vicious cycles in the development of sepsis-related multiorgan dysfunction.","PeriodicalId":73061,"journal":{"name":"Frontiers in aging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0